NCT06083857 2026-03-11PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting3 enrolled
NCT03940703 2026-02-27A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)EMD SeronoPhase 2 Active not recruiting140 enrolled 47 charts
NCT06031688 2026-01-23Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2 Recruiting56 enrolled
NCT06908993 2025-12-17COMETIntergroupe Francophone de Cancerologie ThoraciquePhase 3 Recruiting133 enrolled
NCT05782361 2025-08-20POTENTInstitute of Cancer Research, United KingdomPhase 1 Recruiting19 enrolled